期刊文献+

1例房颤合并糖尿病患者抗凝治疗的病例分析 被引量:2

Analysis of Anticoagulant Therapy of One Case of Atrial Fibrillation Combined with Diabetes Mellitus
原文传递
导出
摘要 目的探讨临床药师在房颤患者个体化抗凝治疗与用药监护中的工作要点。方法参与心内科1例老年非瓣膜病房颤合并糖尿病患者预防栓塞并发症的华法林抗凝治疗用药方案的制订与用药监护。结果确定符合患者特点的抗凝强度,华法林和肝素的配合方法,通过临床药师的用药教育提高患者自我监测和对影响因素的关注。结论个体化用药方案的设计与分析及用药监护是临床药师开展药学服务工作的切入点。 OBJECTIVE To explore the key points of work for clinical pharmacists in individualized anticoagulant therapy in patients with atrial fibrillation. METHODS The pharmacists participated in the development of the regimen of warfarin anticoagulation and its supervision for prevention of embolism complications in one case of aged patient with non valvular disease combined with diabetes. RESULTS The anticoagulant intensity and the combination regiment of warfarin with heparin were determined according to the characteristics of the patient. Patient self-monitoring and awareness of influencing factors were improved through the medical education by clinical pharmacists. CONCLUSION Design of individualized medication regimen and medication supervision should be the breakthrough point of clinical pharmacists.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第11期948-950,共3页 Chinese Pharmaceutical Journal
关键词 房颤 糖尿病 抗凝 华法林 病例分析 atrial fibrillation diabetes mellitus anticoagulation warfarin case analysis
  • 相关文献

参考文献1

二级参考文献27

  • 1王海鹰,荆志成,李崇剑,王建德,徐希奇,邓可武.肺栓塞患者华法林抵抗现象一例及文献回顾[J].中华心血管病杂志,2004,32(11):1039-1040. 被引量:6
  • 2胡荣,杜昕,马长生.华法林在房颤抗凝治疗中的应用[J].药物不良反应杂志,2004,6(6):366-368. 被引量:8
  • 3张海英,张斌,李玉珍.华法林的相互作用及其安全应用[J].药物不良反应杂志,2007,9(2):112-116. 被引量:65
  • 4Ansell J,Hirsh J,Poller L,et al.The pharmacology and management of the vitamin K antagonists:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J].Chest,2004,126(3 Suppl):204s-233s.
  • 5Miners JO,Birkett DJ.Cytochrome P4502C9:an enzyme of major importance in human drug metabolism[J].Br J Clin Pharmacol,1998,45(6):525-538.
  • 6Scordo MG,Pengo V,Spina E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance[J].Clin Pharmacol Ther,2002,72(6):702-710.
  • 7Palkimas MP,Skinner HM,Gandhi PJ,et al.Polymorphism induced sensitivity to warfarin:a review of the literature[J].J Thromb Thrombolysis,2003,15(3):205-212.
  • 8Furuya H,Fernandez-Salguero P,Gregory W,et al.Gennetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J].Pharmacogenetics,1995,5(6):389-392.
  • 9Aithal GP,Day CP,Kesteven PJ,et al.Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarindose requirement and risk of bleeding complications[J].Lancet,1999,353(9154):717-719.
  • 10Higashi MK,Veenstra DL,Kondo LM,et al.Association between CYP2C9 genetic variants and antcoagula tionrelated outcomes during warfarin therapy[J].JAMA,MA,2002,287(13):1690-1698.

共引文献101

同被引文献8

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部